Earnings Call Excerpt
AtriCure Inc. (ATRC)
Q4 2007 Earnings Call
February 14, 2008 10:00 am ET
Executives
David Drachman - President and CEO
Julie Piton - VP of Finance and Administration and CFO
Analyst
Suraj Kalia - Piper Jaffray
Charley Jones - Barrington Research
Matt Dolan - Roth Capital Partners
Larry Haimovitch - HMTC
Steve Ogilvie - ThinkEquity
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Fourth Quarter and Full Year 2007 Earnings Call for AtriCure. My name is Annie, and I'll be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes.
And I would now like to turn the call over to Mr. David Drachman, President and Chief Executive Officer of AtriCure. Mr. Drachman, please proceed.
David Drachman
Thank you, Annie. Good morning, and welcome to AtriCure's fourth quarter and full year 2007 earnings conference call. Joining me on the call today is Julie Piton, Vice President of Finance and Administration and Chief Financial Officer.
At this time, I would like to turn the call over to Julie for a few introductory comments.
Julie Piton
Thank you, Dave. And good morning, everyone. By now you should have received a copy of the earnings press release. If you have not received a copy, please call Sarah Wichman at 513-755-4136 and she will fax or e-mail you a copy.
Before we begin, let me remind you that the Company's remarks today may include forward-looking statements. These statements include, but are not limited to those that address activities, events or developments of AtriCure expects, believes or anticipates will or may occur in the future, such as revenue and earning estimates, other predictions of financial performance, launches of new products, and market acceptance of new products.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including, but not limited to the rate and degree of market acceptance of AtriCure's products and other risks and uncertainties described from time to time in our SEC filings.
AtriCure's results may differ materially from those projected on today's call and AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
I would like to remind everyone on the call today that the FDA has not cleared or approved the company's isolator bipolar ablation systems or Pen for the treatment of AF. They have been cleared for the ablation of cardiac tissue.
- To read the full transcript on Seeking Alpha, click here »
